A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Stopped early · Phase 1
Conditions studied: Isocitrate Dehydrogenase Gene Mutation
In brief
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in advanced or metastatic solid tumors with IDH mutation.
Key facts
- Study ID
- NCT04762602
- Run by
- Hutchmed
- People needed
- 42
- Starts
- 2021-02-28
- Expected to finish
- 2025-02-27
- Last updated by the study team
- 2026-03-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Sarcoma Oncology Research Center — Santa Monica, California, United States
- Emory University — Atlanta, Georgia, United States
- University of Iowa — Iowa City, Iowa, United States
- University of Kentucky — Lexington, Kentucky, United States
- Thomas Jefferson University — Philadelphia, Pennsylvania, United States
- UPMC Hillman Cancer — Pittsburgh, Pennsylvania, United States
- Houston Methodist — Houston, Texas, United States
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- Hospital de la Santa creu i Sant Pau — Barcelona, Spain
- Hospital Universitari Vall d'Hebron — Barcelona, Spain
- Hospital Universitario 12 de Octubre — Madrid, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.